Advisors Asset Management Inc. Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Advisors Asset Management Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,767 shares of the biopharmaceutical company’s stock after purchasing an additional 189 shares during the quarter. Advisors Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,311,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Ashton Thomas Private Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the 2nd quarter valued at $26,000. Huntington National Bank increased its position in Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 45 shares during the last quarter. Hollencrest Capital Management bought a new position in Alnylam Pharmaceuticals in the third quarter valued at about $29,000. Washington Trust Advisors Inc. purchased a new position in Alnylam Pharmaceuticals in the third quarter worth about $42,000. Finally, Friedenthal Financial bought a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $51,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $250.98 on Tuesday. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The business has a 50 day simple moving average of $273.13 and a two-hundred day simple moving average of $238.67. The stock has a market capitalization of $32.37 billion, a PE ratio of -95.79 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analysts’ expectations of $532.91 million. The business’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same period in the previous year, the business posted $1.15 earnings per share. On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.21 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on ALNY shares. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research note on Friday, November 1st. Wolfe Research cut shares of Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research note on Tuesday, November 12th. Bank of America upped their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Scotiabank lifted their target price on Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research report on Friday, November 1st. Finally, HC Wainwright restated a “buy” rating and issued a $400.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.